| P50 | author | Robert D Odze | Q87995042 |
| P2093 | author name string | John R Goldblum | |
| | Patricia A Welsh | |
| | Douglas B Stairs | |
| | Dipti M Karamchandani | |
| | Sara E Ohanessian | |
| | Heather L Lehman | |
| | Julie Massé | |
| | Arthur S Berg | |
| P2860 | cites work | Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction | Q81364447 |
| | Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence | Q82599881 |
| | Diagnosis and grading of dysplasia in Barrett's oesophagus | Q34571587 |
| | Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus | Q34761782 |
| | Hallmarks of cancer progression in Barrett's oesophagus | Q35005134 |
| | c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia | Q35176152 |
| | The role of Cdx proteins in intestinal development and cancer | Q35770120 |
| | The association between vitamin D receptor expression and prolonged overall survival in breast cancer. | Q35955890 |
| | Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions | Q36082215 |
| | Advances in Barrett's esophagus and esophageal adenocarcinoma | Q36123792 |
| | Clinical use of p53 in Barrett's esophagus | Q36533704 |
| | Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis | Q37018235 |
| | A clinical risk prediction model for Barrett esophagus. | Q37114501 |
| | Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies | Q37232101 |
| | Evaluation and treatment of superficial esophageal cancer | Q37598619 |
| | Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process | Q38005810 |
| | Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel | Q38230762 |
| | Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus | Q38323804 |
| | Overdiagnosis of high-grade dysplasia in Barrett's esophagus: a multicenter, international study | Q38353516 |
| | Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial | Q38433659 |
| | Potential application of p53 as an intermediate biomarker in Barrett's esophagus | Q38483936 |
| | Amplification and overexpression of TP63 and MYC as biomarkers for transition of cervical intraepithelial neoplasia to cervical cancer | Q39224196 |
| | Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene | Q39560761 |
| | Differential expression of the nuclear receptors farnesoid X receptor (FXR) and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's oesophagus. | Q39782750 |
| | A 15-year review of esophagectomy for carcinoma of the esophagus and cardia. | Q40532685 |
| | Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study. | Q43875208 |
| | AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease | Q44893022 |
| | Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. | Q45241541 |
| | p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. | Q50974656 |
| | p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. | Q52944800 |
| | Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. | Q53023140 |
| | CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. | Q53494631 |
| | TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus | Q58409008 |
| | [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue] | Q68175965 |
| | Observer variation in the diagnosis of dysplasia in Barrett's esophagus | Q68267912 |
| | p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study | Q72638571 |
| | Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma | Q73147250 |
| | The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression | Q73382840 |
| | Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia | Q80203648 |
| | Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium | Q80332843 |
| | The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 |
| | Radiofrequency ablation in Barrett's esophagus with dysplasia | Q28246453 |
| | CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer | Q28251382 |
| | Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus | Q33611018 |
| | Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation | Q34238141 |
| | Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study | Q34238147 |
| | Molecular basis of esophageal cancer development and progression | Q34303046 |
| P921 | main subject | Barrett's esophagus | Q808892 |
| | immunohistochemistry | Q899285 |
| P304 | page(s) | 23 | |
| P577 | publication date | 2016-02-29 | |
| P1433 | published in | Diagnostic Pathology | Q18397261 |
| P1476 | title | Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1 | |
| P478 | volume | 11 | |